Jan 22nd, 2024
New Study Published in JAMA Neurology Affirms High Diagnostic Accuracy of ALZpath’s pTau217 Test in Identifying Amyloid and Tau in the Brain
CARLSBAD, Calif., — January 22, 2024 — ALZpath, Inc. (ALZpath), a leader in Alzheimer’s diagnostics, announced new findings published online today in JAMA Neurology showing that its proprietary blood-based biomarker assay for phosphorylated tau at residue 217 (pTau217) delivers high diagnostic accuracy and consistency in identifying amyloid and tau in the brain. The article, “Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer’s Disease Pathology,” was authored by Dr. Nicholas Ashton and colleagues from the University of Gothenburg, Sweden.
Cerebrospinal fluid (CSF) biomarkers are considered one of the most accurate tests of Alzheimer’s pathology available, in addition to positron emission tomography (PET) imaging. However, CSF testing is significantly more invasive than blood tests, requiring a painful spinal tap procedure, at a cost typically 2-3 times higher than blood-based testing, and is more difficult to administer at the scale that will be required with the availability of a new generation of disease-modifying treatments.
ALZpath is a leading provider of innovative diagnostic solutions for Alzheimer’s disease. With the novel ALZpath pTau217 assay and test, ALZpath is transforming Alzheimer’s disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. The study employed the ALZpath pTau217 ultra-sensitive immunoassay, developed on the Single molecule array (SimoaTM) platform in blood, and evaluated the performance of the ALZpath pTau217 assay in three independent clinical studies as part of an international collaboration between researchers in Sweden, Spain, Canada and the US. The combined studies included 786 participants.
The ALZpath pTau217 assay showed high diagnostic accuracy in identifying elevated amyloid (AUC, 0.92-0.96; 95%CI 0.89-0.99) and tau (AUC, 0.93-0.97; 95%CI 0.84-0.99) in the brain across all cohorts. These accuracies were significantly higher than other plasma biomarker combinations and equivalent to CSF biomarkers. The classification of individuals with abnormal amyloid using a binary or two-cut off model yielded reproducible results across the three independent studies in this publication. Longitudinally, ALZpath’s pTau217 test in blood showed an annual increase in individuals with amyloid plaques, with the highest increase observed in those who also had tau pathology.
“This is an instrumental finding in blood-based biomarkers for Alzheimer’s, paving the way for the clinical use of the ALZpath pTau 217 assay,” stated Professors Kaj Blennow and Henrik Zetterberg from the University of Gothenburg, co-authors on the publication. “This robust assay is already used in multiple labs around the globe.”
“ALZpath’s pTau217 test can help healthcare providers determine the presence of amyloid plaques in the brain – a hallmark of Alzheimer’s disease,” said Dr. Andreas Jeromin, ALZpath Chief Scientific Officer. “This diagnostic capability offers increasingly vital aid in medical management and treatment decisions for Alzheimer’s, especially as new disease-modifying treatments become more accessible.”
The ALZpath pTau217 assay will be available for clinical use as ALZpath Dx later this month and is part of a broader neuro biomarker portfolio in development. The ALZpath pTau217 test will also be commercially available on other research and diagnostic platforms in support of global accessibility and scalability.
About ALZpath
ALZpath is a leading provider of innovative diagnostic solutions for Alzheimer’s disease. With the novel ALZpath pTau217 Assay, ALZpath is transforming Alzheimer’s disease diagnosis and monitoring, providing accurate and accessible tools for researchers and healthcare professionals worldwide. To learn more about the company visit https://alzpath.bio/.
The company acknowledges generous support from, Alzheimer’s Drug Discovery Foundation/ Gates Ventures. For more information www.alzpath.bio
Company Contact
Andreas Jeromin
Chief Scientific Officer, PhD., MD
ALZpath
Media Contact
Nechama Rosengarten
FINN Partners
Nechama.Rosengarten@finnpartners.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on ALZpath’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause ALZpath’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in ALZpath’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, ALZpath assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
